NO20062118L - Inhibitor kontrastmidler - Google Patents

Inhibitor kontrastmidler

Info

Publication number
NO20062118L
NO20062118L NO20062118A NO20062118A NO20062118L NO 20062118 L NO20062118 L NO 20062118L NO 20062118 A NO20062118 A NO 20062118A NO 20062118 A NO20062118 A NO 20062118A NO 20062118 L NO20062118 L NO 20062118L
Authority
NO
Norway
Prior art keywords
contrast agents
inhibitor contrast
inhibitor
contrast
mmps
Prior art date
Application number
NO20062118A
Other languages
English (en)
Inventor
Magne Solbakken
Alan Cuthbertson
Emma Bjurgert
Original Assignee
Ge Healthcare Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ge Healthcare Ltd filed Critical Ge Healthcare Ltd
Publication of NO20062118L publication Critical patent/NO20062118L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/18—Sulfonamides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/6425—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the peptide or protein in the drug conjugate being a receptor, e.g. CD4, a cell surface antigen, i.e. not a peptide ligand targeting the antigen, or a cell surface determinant, i.e. a part of the surface of a cell
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/0002—General or multifunctional contrast agents, e.g. chelated agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/04—X-ray contrast preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/088—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins conjugates with carriers being peptides, polyamino acids or proteins

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Optics & Photonics (AREA)
  • Physics & Mathematics (AREA)
  • Radiology & Medical Imaging (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cell Biology (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Addition Polymer Or Copolymer, Post-Treatments, Or Chemical Modifications (AREA)
  • Transition And Organic Metals Composition Catalysts For Addition Polymerization (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

Foreliggende oppfinnelse angår konfrastmidler som omfatter en spesifikk type matriks metaUoproteinaseinhibitorer (MMPi'er) av sulfonamid hydroksamatklassen merket med en kontrastgivende enhet er nyttige kontrastmidler for in vivo bildedannelse og diagnose av pattedyrlegemer.
NO20062118A 2003-11-14 2006-05-11 Inhibitor kontrastmidler NO20062118L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0326546.9A GB0326546D0 (en) 2003-11-14 2003-11-14 Inhibitor imaging agents
PCT/GB2004/004792 WO2005049005A1 (en) 2003-11-14 2004-11-12 Inhibitor imaging agents

Publications (1)

Publication Number Publication Date
NO20062118L true NO20062118L (no) 2006-05-11

Family

ID=29726529

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20062118A NO20062118L (no) 2003-11-14 2006-05-11 Inhibitor kontrastmidler

Country Status (16)

Country Link
US (1) US20070104644A1 (no)
EP (1) EP1682113B1 (no)
JP (1) JP5043438B2 (no)
KR (1) KR20060118479A (no)
CN (1) CN1901894A (no)
AT (1) ATE384519T1 (no)
AU (1) AU2004290950A1 (no)
BR (1) BRPI0416528A (no)
CA (1) CA2545267A1 (no)
DE (1) DE602004011553T2 (no)
ES (1) ES2299884T3 (no)
GB (1) GB0326546D0 (no)
MX (1) MXPA06005355A (no)
NO (1) NO20062118L (no)
RU (1) RU2006117298A (no)
WO (1) WO2005049005A1 (no)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW200630337A (en) * 2004-10-14 2006-09-01 Euro Celtique Sa Piperidinyl compounds and the use thereof
WO2007030012A2 (en) * 2005-09-05 2007-03-15 Stichting Voor De Technische Wetenscahappen Extracellular matrix imaging
FR2891830B1 (fr) 2005-10-07 2011-06-24 Guerbet Sa Composes a chaines aminoalcools courtes et complexes metalliques pour l'imagerie medicale
GB0520527D0 (en) * 2005-10-10 2005-11-16 Ge Healthcare Ltd Automated method
EP1989179B1 (en) 2006-02-15 2011-01-26 Ge Healthcare As Contrast agents
WO2007110449A1 (en) * 2006-03-29 2007-10-04 Euro-Celtique S.A. Benzenesulfonamide compounds and their use
WO2007117981A2 (en) * 2006-03-29 2007-10-18 Novartis Ag Selective hydroxamate based mmp inhibitors
US8791264B2 (en) * 2006-04-13 2014-07-29 Purdue Pharma L.P. Benzenesulfonamide compounds and their use as blockers of calcium channels
WO2007118854A1 (en) * 2006-04-13 2007-10-25 Euro-Celtique S.A. Benzenesulfonamide compounds and the use thereof
GB0610395D0 (en) * 2006-05-25 2006-07-05 Ge Healthcare Ltd Novel imaging agents
US8273325B2 (en) * 2006-12-20 2012-09-25 Ge Healthcare As Contrast agents
US8399486B2 (en) * 2007-04-09 2013-03-19 Purdue Pharma L.P. Benzenesulfonyl compounds and the use thereof
US8765736B2 (en) * 2007-09-28 2014-07-01 Purdue Pharma L.P. Benzenesulfonamide compounds and the use thereof
EP2119690A1 (en) * 2008-05-14 2009-11-18 Academisch Medisch Centrum bij de Universiteit van Amsterdam Radiolabelled MMP selective compounds
JP5322527B2 (ja) * 2008-07-17 2013-10-23 浜松ホトニクス株式会社 アポトーシスの検出に適した化合物
EP2147684A1 (en) 2008-07-22 2010-01-27 Bracco Imaging S.p.A Diagnostic Agents Selective Against Metalloproteases
WO2010138720A2 (en) * 2009-05-27 2010-12-02 The Scripps Research Institute Compounds and methods for chelating metals in aqueous solutions
WO2011000958A1 (en) 2009-07-03 2011-01-06 INSERM (Institut National de la Santé et de la Recherche Médicale) Compounds targeting the cation-independent mannose 6-phosphate receptor
CN103002952B (zh) 2009-10-29 2017-02-15 宝洁公司 包含阳离子表面活性剂体系、直接染料和非离子增稠剂的毛发调理组合物
US9023318B2 (en) * 2011-06-08 2015-05-05 Siemens Medical Solutions Usa, Inc. Compounds with matrix-metalloproteinase inhibitory activity and imaging agents thereof
US8871189B2 (en) * 2011-11-30 2014-10-28 Mallinckrodt Llc MMP-targeted therapeutic and/or diagnostic nanocarriers
CN103980277B (zh) * 2014-05-27 2016-06-15 青岛大学 一种叶酸巯基化衍生物的制备方法
GB202012671D0 (en) * 2020-08-13 2020-09-30 Nrf Ithemba Labs Theranostic Compounds

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5714465A (en) * 1989-05-19 1998-02-03 Amgen Inc. Method of inhibiting tumor cell dissemination with a metalloproteinase inhibitor
US5863949A (en) * 1995-03-08 1999-01-26 Pfizer Inc Arylsulfonylamino hydroxamic acid derivatives
CN1171866C (zh) * 1997-08-08 2004-10-20 辉瑞产品公司 芳氧基芳基磺酰氨基异羟肟酸衍生物
EP0895988B1 (en) * 1997-08-08 2002-05-22 Pfizer Products Inc. Arylsulfonylamino hydroxamic acid derivatives
IL127496A0 (en) * 1997-12-19 1999-10-28 Pfizer Prod Inc The use of MMP inhibitors for the treatment of ocular angiogenesis
PT952148E (pt) * 1998-04-10 2004-09-30 Pfizer Prod Inc Derivados de acido ciclobutil-ariloxiarilsulfonilamino-hidroxamico
DK1210326T3 (da) * 1999-08-18 2004-06-21 Warner Lambert Co Hydroxamsyreforbindelser, der er nyttige som matrixmetalloproteinaseinhibitorer
IL138686A0 (en) * 1999-10-01 2001-10-31 Pfizer Prod Inc α- SULFONYLAMINO HYDROXAMIC ACID INHIBITORS OF MATRIX METALLOPROTEINASES FOR THE TREATMENT OF PERIPHERAL OR CENTRAL NERVOUS SYSTEM DISORDERS
US6656448B1 (en) * 2000-02-15 2003-12-02 Bristol-Myers Squibb Pharma Company Matrix metalloproteinase inhibitors
AU2001265182A1 (en) * 2000-05-30 2001-12-11 Rafael Fridman Inhibitors of matrix metalloproteinases
WO2004069365A1 (en) * 2003-02-10 2004-08-19 Ge Healthcare Limited Diagnostic imaging agents with mmp inhibitory activity

Also Published As

Publication number Publication date
DE602004011553T2 (de) 2009-03-26
ES2299884T3 (es) 2008-06-01
ATE384519T1 (de) 2008-02-15
CN1901894A (zh) 2007-01-24
JP5043438B2 (ja) 2012-10-10
EP1682113A1 (en) 2006-07-26
DE602004011553D1 (de) 2008-03-13
KR20060118479A (ko) 2006-11-23
JP2007511494A (ja) 2007-05-10
GB0326546D0 (en) 2003-12-17
WO2005049005A1 (en) 2005-06-02
RU2006117298A (ru) 2007-12-20
EP1682113B1 (en) 2008-01-23
US20070104644A1 (en) 2007-05-10
CA2545267A1 (en) 2005-06-02
BRPI0416528A (pt) 2007-01-09
AU2004290950A1 (en) 2005-06-02
MXPA06005355A (es) 2006-07-10

Similar Documents

Publication Publication Date Title
NO20062118L (no) Inhibitor kontrastmidler
NO20072120L (no) Enzyme Inhibitor Imaging Agents
EP1547996A4 (en) DIAGNOSTIC PROBES AND REMEDIES FOR DISEASES HAVING PRION PROTEIN ACCUMULATION AND METHOD OF MARKING
EA201000542A1 (ru) Способы, устройства, системы, комплекты и наборы для отведения тканей в ротовой полости
RS51213B (sr) Farmaceutski vaginalni gel koji sadrži tenofovir
UY27972A1 (es) Derivados de hidantoína
BR0313371A (pt) Composto, uso de um composto e método de tratamento de doença
NO20024402D0 (no) Cykliske <beta>-aminosyrederivater som inhibitorer av matriksmetalloproteaser og TNF-<alfa>
ATE418967T2 (de) Matrix für die modifizierte freigabe von aktiven substanzen
BRPI0414030A (pt) método para detectar desordens neoplásicas em uma amostra corporal solubilizada
DE602005003570D1 (de) Rohr- und universalkupplung für die zufuhr von zahnmedizinischen oder chirurgischen instrumenteen
DE60305906D1 (de) Okklusionszusammensetzung umfassend ein poly(2-cyanoacrylat)-monomer
DE60302995D1 (de) Blutdruckmessgerät
NO20053776L (no) Diagnostic imaging agents with MMP inhibitory activity
CY1108540T1 (el) Ταυτοποιηση θεραπευτικων ενωσεων
CY1110130T1 (el) Παραγωγα μορφολινης για χρηση ως αγωνιστες ντοπαμινης στην θεραπευτικη αγωγη σεξουαλικης δυσλειτουργιας i.α.
ATE519505T1 (de) Reaktive paramagnetische kontrastmittel für magnetresonanzbildgebung
DE502004005226D1 (de) Diagnosestellung von akuten myokardialen, ischämischen erkrankungen durch kombination von markern
BRPI0515161A (pt) substratos enzimáticos derivados de fenoxazinona e seu uso como revelador na detecção de microorganismos com atividade de peptidase
EA200801875A1 (ru) Антагонист cd 80
WO2001088533A3 (en) Lipid uptake assays
BR0317404A (pt) Variantes do fator xiia
ITMI20021976A1 (it) Procedimento e dispositivo per la diagnosi di uno smorzatore di pressioni.
AU2003235113A1 (en) Method of measuring neprilysin activity
ITTO20040345A1 (it) Apparecchio di prova per l'esecuzione di prove hdt e vicat.

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application